Profile:
Bedaquiline fumarate (CAS No.: 843663-66-1) is a first-in-class diarylquinoline anti-tuberculosis (anti-TB) agent—the first novel anti-TB drug approved for clinical use in nearly 50 years—and a core therapeutic agent for drug-resistant tuberculosis recommended by the World Health Organization (WHO). It features a unique mechanism of action distinct from traditional anti-TB drugs, with potent bactericidal and bacteriostatic activity against Mycobacterium tuberculosis (MTB), including drug-resistant strains. Its core mechanism is selectively inhibiting the ATP synthase of MTB (a proton pump on the bacterial cell membrane), blocking the synthesis of adenosine triphosphate (ATP)—the primary energy source for bacterial metabolism and reproduction. This action disrupts the energy supply of MTB, leading to bacterial death, and it is effective against both replicating and non-replicating (dormant) MTB, a key advantage over many conventional anti-TB drugs.
Bedaquiline fumarate is clinically indicated for the treatment of drug-resistant tuberculosis (the only core indication approved globally) and is used as a key component of combination anti-TB therapy (never as monotherapy) due to the high risk of drug resistance development in MTB. Its detailed clinical uses, applicable populations and therapeutic scenarios are systematically summarized below, in line with the latest WHO anti-TB treatment guidelines (2024):
1. Primary Clinical Use: Treatment of Multidrug-Resistant Tuberculosis (MDR-TB)
This is the most common and core approved indication of bedaquiline fumarate, covering rifampicin-resistant tuberculosis (RR-TB) (the primary subset of MDR-TB) and full MDR-TB (resistant to at least rifampicin and isoniazid, the two first-line core anti-TB drugs).
It is listed as a Group A core drug in the WHO MDR-TB treatment regimen, the first-choice oral anti-TB drug for constructing all-oral MDR-TB treatment regimens (replacing injectable second-line anti-TB drugs such as amikacin and capreomycin).
It is used for the treatment of pulmonary MDR-TB (the most common form) and extrapulmonary MDR-TB (e.g., lymph node, pleural, bone and joint TB) in adults and pediatric patients, effectively reducing the bacterial load in the body, alleviating clinical symptoms (cough, hemoptysis, fever, fatigue) and promoting the healing of TB lesions.
The all-oral regimen containing bedaquiline fumarate has significantly improved the cure rate of MDR-TB (up to 85% or higher) and reduced the adverse reactions associated with traditional injectable regimens, greatly improving patient medication compliance and quality of life.
2. Key Clinical Use: Treatment of Extensively Drug-Resistant Tuberculosis (XDR-TB)
Bedaquiline fumarate is the cornerstone drug for the treatment of XDR-TB—a severe form of drug-resistant TB defined as resistance to rifampicin, isoniazid, any fluoroquinolone (e.g., moxifloxacin) and any second-line injectable anti-TB drug.
XDR-TB has extremely limited treatment options with traditional anti-TB drugs and a very low cure rate; bedaquiline fumarate is the core component of the WHO-recommended XDR-TB salvage treatment regimen, often combined with other novel anti-TB drugs (e.g., pretomanid, delamanid) and effective second-line drugs (e.g., linezolid, clofazimine) to form a personalized combination regimen.
It exerts a potent bactericidal effect on XDR-TB strains, even for MTB resistant to multiple anti-TB drugs, and its long half-life (~5.5 months) enables sustained drug concentration in the body, effectively eliminating dormant MTB and reducing the risk of treatment failure and relapse.
3. Expanded Clinical Uses (WHO-Recommended Compassionate Use)
Based on its excellent anti-TB activity and good tolerability, bedaquiline fumarate is also recommended by the WHO for compassionate use in other difficult-to-treat TB scenarios, under the guidance of clinical anti-TB specialists:
Intolerant or non-responsive TB to first/second-line regimens: For patients with drug-susceptible TB who cannot tolerate traditional first-line anti-TB drugs (e.g., severe liver/kidney toxicity from isoniazid/rifampicin) or patients with MDR-TB who have poor response to conventional second-line regimens, bedaquiline fumarate can be included in the regimen for salvage treatment.
Pediatric drug-resistant TB (≥5 years old or body weight ≥15 kg): Approved for use in pediatric patients with MDR/XDR-TB (oral dispersible tablets for children are available), it is the first novel oral anti-TB drug for children, filling the gap in the treatment of pediatric drug-resistant TB.
TB in special populations: For patients with TB complicated by HIV/AIDS (a high-risk group for drug-resistant TB), bedaquiline fumarate has no significant drug-drug interactions with core antiretroviral drugs (ARVs) and is a safe and effective choice for combination therapy, effectively controlling both TB and HIV replication without affecting the efficacy of ARVs. It is also used for TB patients with mild to moderate liver/renal insufficiency (dose adjustment is not required in most cases), with a wide therapeutic window.
4. Off-Label Clinical Application (Evidence-Based Use)
In clinical practice, bedaquiline fumarate is also used off-label for the treatment of non-tuberculous mycobacterial (NTM) diseases (based on clinical evidence and expert consensus), a group of infectious diseases caused by non-MTB mycobacteria (e.g., Mycobacterium avium complex, MAC; Mycobacterium abscessus):
It is used for the treatment of drug-resistant NTM pulmonary disease (the most common NTM disease) that is unresponsive to traditional anti-NTM regimens, exerting a potent inhibitory effect on a variety of NTM strains by targeting mycobacterial ATP synthase.
It is often combined with azithromycin, clarithromycin, moxifloxacin and other anti-NTM drugs to form a personalized regimen, improving the treatment response rate of drug-resistant NTM diseases.
China
